Results 211 to 220 of about 15,321 (234)
Some of the next articles are maybe not open access.
A direct access to heptasubstituted biguanides
Molecular Diversity, 2015An efficient and experimentally simple copper-catalyzed carbon-nitrogen bond formation for the synthesis of [Formula: see text]-arylated biguanides starting from aryl halides, carbodiimides, and 1,1,3,3-tetramethylguanidine is reported. The potential diversity of this type of reaction, easily available starting materials, and commercially available low-
Issa Yavari, Manijeh Nematpour
openaire +3 more sources
ChemInform Abstract: Structure of Various Biguanides and Metal Complexes of Biguanides
ChemInform, 1995AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
openaire +2 more sources
Metformin: a new oral biguanide
Clinical Therapeutics, 1996The biguanide metformin is an oral anti-hyperglycemic agent used in the treatment of patients with non-insulin-dependent diabetes mellitus (NIDDM). Metformin is an important addition to the drug therapy options available for those patients because it reduces blood glucose levels predominantly by decreasing hepatic glucose production and release and ...
John R. White +2 more
openaire +3 more sources
Biguanides and Gastric Emptying in Man
Digestion, 1971In contrast to its effect in animal experiments, biguanide is shown to have no effect on gastric emptying in man.
W. Berger, M. Eisner
openaire +3 more sources
Effect of biguanides and atromid on fibrinolysis
Journal of Atherosclerosis Research, 1967Summary The effects of phenformin, metformin, and Atromid on blood fibrinolytic activity, plasma fibrinogen, and serum cholesterol levels were compared in a study of 36 out-patients with occlusive vascular disease. Atromid was the least satisfactory fibrinolytic drug, having only a transient effect on the blood clot lysis time, though a more ...
Elizabeth D. Hocking +3 more
openaire +3 more sources
Review of Biguanide (Metformin) Toxicity
Journal of Intensive Care Medicine, 2018In the 1920s, guanidine, the active component of Galega officinalis, was shown to lower glucose levels and used to synthesize several antidiabetic compounds. Metformin (1,1 dimethylbiguanide) is the most well-known and currently the only marketed biguanide in the United States, United Kingdom, Canada, and Australia for the treatment of non-insulin ...
Christopher Hoyte +3 more
openaire +3 more sources
Biguanid-induzierte Laktatazidose
1995Es gibt Angaben, das das Risiko einer Laktatazidose unter Metformintherapie bei 0,024-0,084 Fallen pro 1000 Patientenjahre lage. Das entspricht 1:11000 bis 1:40 000 der Metformin-behandelten Patienten pro Jahr. Die Mortalitat ist nochmal um den Faktor 3 geringer. Die beschriebenen Todesfalle traten bei Patienten mit Kontraindikationen fur Metformin auf.
openaire +2 more sources
Environmental Fate of Polyhexamethylene Biguanide
Bulletin of Environmental Contamination and Toxicology, 2011Polyhexamethylene biguanide (PHMB) is used as a bacteriocidal agent in a variety of applications from medical devices to pools, but is highly toxic to some aquatic species. The stability of PHMB in various environmental matrices was examined. 80% of PHMB was present in fortified creek samples after 20 days, but bound immediately to soils with the ...
openaire +3 more sources
Clinical Pharmacology of Biguanides
1996The biguanide drugs have been used to treat hyperglycaemia in non-insulin-dependent diabetes mellitus (NIDDM) for almost 40 years (Sterne 1969; Hermann 1979; Schafer 1983; Bailey 1992). Repeated reports of phenformin-associated lactic acidosis led to the withdrawal of this biguanide in the United States in 1977 and in most other countries.
openaire +2 more sources
Journal of the Chemical Society A: Inorganic, Physical, Theoretical, 1969
A series of quadricovalent cationic complexes of silver(III) with biguanide and with methylbiguanide having the composition [AgIIIL2]X3, where L is a bidentate ligand and X a univalent anion, has been prepared and characterised. In alkaline, neutral, and feebly acidic medium (pH > 5), the biguanide molecule possesses filled π-type delocalised orbitals.
openaire +2 more sources
A series of quadricovalent cationic complexes of silver(III) with biguanide and with methylbiguanide having the composition [AgIIIL2]X3, where L is a bidentate ligand and X a univalent anion, has been prepared and characterised. In alkaline, neutral, and feebly acidic medium (pH > 5), the biguanide molecule possesses filled π-type delocalised orbitals.
openaire +2 more sources